Work Here?
Mallinckrodt
Work Here?
Specialty pharmaceutical developer, manufacturer, distributor
Mallinckrodt
Work Here?
Specialty pharmaceutical developer, manufacturer, distributor
Overview
Mallinckrodt is a global specialty pharmaceutical company that develops, manufactures, and distributes drugs and therapies for complex and rare conditions, serving healthcare providers, hospitals, and patients mainly in the United States and Europe. Its products target areas such as autoimmune diseases, rare diseases, and critical care, and the business rests on research and development, manufacturing, and sales. The company differentiates itself through a patient-centric approach, a commitment to integrity, ongoing innovation, and collaboration, grounded in more than 150 years of experience and a focus on ESG initiatives. Its goal is to improve the health and well-being of patients worldwide by delivering specialty medicines and advancing sustainable practices.
About Mallinckrodt
Industries
Industrial & Manufacturing
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Hazelwood, Missouri
Founded
1867
Get referred to Mallinckrodt
See people who can refer or advise you
Simplify's Take
What believers are saying
- Rare-disease and autoimmune products support premium pricing and physician-driven demand.
- US manufacturing strengthens supply-chain appeal for hospitals and policymakers.
- Post-Endo portfolio breadth expands cross-selling across branded therapeutics and generics.
What critics are saying
- Specialty generics face commoditization and persistent margin compression.
- Legacy opioid liabilities still threaten cash flow and future restructuring.
- Narrow product concentration creates sharp revenue loss from exclusivity or formulary setbacks.
What makes Mallinckrodt unique
- Specialty portfolio spans autoimmune, rare disease, neonatal respiratory, and critical care therapies.
- Keenova Therapeutics and Par Health create clearer branded and generics focus.
- Dublin headquarters with U.S. operations supports global reach and domestic execution.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$6.7B
Above
Industry Average
Funded Over
1 Rounds
Benefits
Performance Bonus
Relocation Assistance
Stock Price
Growth & Insights and Company News
6 month growth
↓ -5%1 year growth
↓ -5%2 year growth
↓ -5%Launches as Top 15 U.S. Generic Drug Manufacturer, Largest U.S. Producer of Active Pharmaceutical Ingredients and Premier U.S. Producer of Sterile Injectables...
Mallinckrodt plc appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025.
Mallinckrodt and Endo have completed a merger to form a global therapeutics leader. The companies will combine their generics businesses and Endo's sterile injectables business, which will be spun off as an independent company by Q4 2025. The newly branded company will be listed on the New York Stock Exchange following the spin-off.
Mallinckrodt has reached a milestone in a $7 billion merger deal.
Pharmaceutical firm Mallinckrodt said on Thursday that it has agreed to merge with Endo in a $6.7bn deal.
Mallinckrodt is Hiring for 28 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Mallinckrodt
Industries
Industrial & Manufacturing
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Hazelwood, Missouri
Founded
1867
Mallinckrodt is Hiring for 28 Jobs on Simplify!
Find jobs on Simplify and start your career today